GDTC SEC Filing News — CytoMed Therapeutics Limited

Latest SEC filings for CytoMed Therapeutics Limited (GDTC) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-11.

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a …
Sector: Healthcare Industry: Biotechnology Market Cap: $10.5M CIK: 1873093
9
Total Filings
2
Bullish Classifications
0
Bearish Classifications
2
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for GDTC currently lean bullish. Of the 9 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 2 insider transactions (Form 4) in this period.
GDTC Filing Activity Snapshot 2024-11-04 — 2026-08-11
Insider Transactions (Form 4)
2 buys vs 0 sells
Net insider buying in this period — more purchases than sales reported.
Largest Form 144 Filing
$300.0K
Choo Chee Kong (Director, 10% Owner) · 2026-07-24
200,000 shares · Form 4
Form 144 Notices
7
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 2 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 2 filings in this group are Form 4s for CytoMed Therapeutics Limited.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 2 insider filings shown, the breakdown is 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×2
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market purchase Insider Buying 2026-07-24

GDTC insider Choo Chee Kong (Director, 10% Owner) bought 200,000 shares (~$300.0K)

Choo Chee Kong, listed as Director, 10% Owner at CytoMed Therapeutics Ltd, reported an open-market purchase of 200,000 GDTC shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 100,000 $1.50 $150.0K
P Open-market purchase 100,000 $1.50 $150.0K
Filing: Form 4 (Insider Transaction) Insider: Choo Chee Kong (Director, 10% Owner) Shares: 200,000 Est. Value: $300.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-06-15

GDTC insider Choo Chee Kong (Director, 10% Owner) bought 112,000 shares (~$128.8K)

Choo Chee Kong, listed as Director, 10% Owner at CytoMed Therapeutics Ltd, reported an open-market purchase of 112,000 GDTC shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 112,000 $1.15 $128.8K
Filing: Form 4 (Insider Transaction) Insider: Choo Chee Kong (Director, 10% Owner) Shares: 112,000 Est. Value: $128.8K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 7 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. CytoMed Therapeutics Limited has 7 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-11

GDTC Form 144 filed for proposed insider sale by mDR Ltd (117,337 shares) ~$103.3K

mDR Ltd filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR Ltd Shares: 117,337 Est. Value: $103.3K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-13

GDTC Form 144 filed for proposed insider sale by mDR LTD (117,337 shares) ~$98.1K

mDR LTD filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR LTD Shares: 117,337 Est. Value: $98.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-02-12

GDTC Form 144 filed for proposed insider sale by mDR LTD (117,337 shares) ~$122.0K

mDR LTD filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR LTD Shares: 117,337 Est. Value: $122.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2025-09-22

GDTC Form 144 filed for proposed insider sale by mDR Ltd (54,644 shares) ~$102.7K

mDR Ltd filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR Ltd Shares: 54,644 Est. Value: $102.7K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2025-06-23

GDTC Form 144 filed for proposed insider sale by mDR Ltd (81,482 shares) ~$171.1K

mDR Ltd filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR Ltd Shares: 81,482 Est. Value: $171.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2025-03-24

GDTC Form 144 filed for proposed insider sale by mDR Ltd (86,410 shares) ~$229.8K

mDR Ltd filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR Ltd Shares: 86,410 Est. Value: $229.8K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2024-11-04

GDTC Form 144 filed for proposed insider sale by mDR Ltd (115,400 shares) ~$266.0K

mDR Ltd filed a Form 144 with the SEC indicating intent to sell GDTC (CytoMed Therapeutics Ltd) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: mDR Ltd Shares: 115,400 Est. Value: $266.0K
View on SEC EDGAR → Open Filing Document →

How we classify CytoMed Therapeutics Limited's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on GDTC. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — GDTC SEC Filings

More Tools for GDTC

GDTC Full Stock Analysis GDTC Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper GDTC analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the GDTC stock analysis page.

GDTC Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer